FIVE NEW REPORTS LAUNCHED BY MEALEY PUBLICATIONS.
An annual subscription to PPA/Ephedra costs $700. Editorial includes data and news on litigation related to the use of phenylpropanolamine (PPA), a common decongestant/appetite suppressant that carries a small but significant risk of severe hemorrhagic stroke in women. Mealey said that PPA lawsuits, scattered over the last 20 years, are expected to increase with the FDA's announcement to ban the drug. The report will carry filings, new complaints, news developments, summaries and trial updates.
|Printer friendly Cite/link Email Feedback|
|Comment:||FIVE NEW REPORTS LAUNCHED BY MEALEY PUBLICATIONS.|
|Article Type:||Brief Article|
|Date:||Apr 30, 2001|
|Previous Article:||INTERTEC ACQUIRES TRADE SHOWS FROM CONTINENTAL EXHIBITIONS.|